切换至 "中华医学电子期刊资源库"
高级检索
中华临床实验室管理电子杂志

中华临床实验室管理电子杂志 ›› 2018, Vol. 06 ›› Issue (04) : 212 -215. doi: 10.3877/cma.j.issn.2095-5820.2018.04.005

所属专题： 文献；

实验研究

霉酚酸浓度监测对肾移植受者移植后感染的预测价值初探
白杨娟1, 石运莹2, 邹远高1, 唐江涛1, 李亚梅1, 王兰兰1,†()   
  1. 1. 610041　成都，四川大学华西医院实验医学科
    2. 610041　成都，四川大学华西医院肾脏内科
  • 收稿日期:2018-08-02 出版日期:2018-11-28
  • 通信作者: 王兰兰

A pilot study on predictive value of mycophenolic acid concentration monitoring in postoperative infection of renal transplant recipients

Yangjuan Bai1, Yunying Shi2, Yuangao Zou1, Jiangtao Tang1, Yamei Li1, Lanlan Wang1,†()   

  1. 1. Department of Laboratory Medicine, West China Hospital, Sichuan University, Chengdu 610041, China
    2. Department of nephrology, West China Hospital, Sichuan University, Chengdu 610041, China
  • Received:2018-08-02 Published:2018-11-28
  • Corresponding author: Lanlan Wang
  • About author:
    Corresponding author: Wang Lanlan, Email:
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

白杨娟, 石运莹, 邹远高, 唐江涛, 李亚梅, 王兰兰. 霉酚酸浓度监测对肾移植受者移植后感染的预测价值初探[J/OL]. 中华临床实验室管理电子杂志, 2018, 06(04): 212-215.

Yangjuan Bai, Yunying Shi, Yuangao Zou, Jiangtao Tang, Yamei Li, Lanlan Wang. A pilot study on predictive value of mycophenolic acid concentration monitoring in postoperative infection of renal transplant recipients[J/OL]. Chinese Journal of Clinical Laboratory Management(Electronic Edition), 2018, 06(04): 212-215.

目的

研究霉酚酸(mycophenolic acid，MPA)浓度监测对肾移植受者移植后感染的预测价值。

方法

纳入四川大学华西医院临床诊断为感染的住院肾移植受者48例(感染组)、一般情况稳定且排除感染的肾移植受者68例(对照组)，收集所有受者入院前、入院时及出院时服药前、服药后0.5 h、2 h、4 h MPA药物浓度(MPA-C0、MPA-C0.5、MPA-C2、MPA-C4)和简化药时曲线下面积(MPA Area Under Curve0-4，MPA-AUC0-4)、他克莫司(Tacrolimus，TAC)谷浓度(TAC-C0)、相关实验室检查、影像学等辅助检查等资料。

结果

感染组肾移植受者TAC-C0在入院前后基本稳定，均接近稳定组水平(P>0.05)。入院前，感染组肾移植受者MPA-AUC0-4及MPA-C4显著高于对照组(P<0.05)，MPA-C0和MPA-C2稍高于与对照组(P>0.05)；入院时，除MPA-C0明显低于对照组(P<0.05)，MPA-C2、 MPA-C4及MPA-AUC0-4在感染组稍低于对照组(P>0.05)；出院时，感染组MPA各时点浓度和MPA-AUC0-4均与对照组无显著差异(P>0.05)。

结论

MPA-AUC0-4、MPA-C4对肾移植受者感染发生有早期预示作用，霉酚酸治疗药物浓度监测有助于肾移植受者感染的预防控制。

关键词: 霉酚酸, 治疗药物浓度监测, 感染, 肾移植
Objective

To investigate the predictive value of mycophenolic acid (MPA) concentration monitoring in postoperative infection on renal transplant recipients.

Methods

Forty-eight hospitalized renal transplant recipients (infection group) and 68 non-infected renal transplant recipients (control group) were enrolled in West China Hospital of Sichuan University. MPA concentration including plasma MPA concentration before dose (MPA-C0), plasma MPA concentration 0.5 h after dose (MPA-C0.5), plasma MPA concentration 2 h after dose (MPA-C2), plasma MPA concentration 4 h after dose (MPA-C4), the simplified MPA AUC (MPA-AUC0-4) and the pre-dose blood concentration of Tacrolimus (TAC-C0), relevant laboratory data, imaging and other auxiliary examination data were analyzed.

Results

In the infected group, the TAC-C0 of the renal transplant recipients was basically stable before and after admission, all near the stability level (P>0.05). Before admission, MPA-AUC0-4 and MPA-C4 of renal transplant recipients in the infected group were significantly higher than those in the control group (P<0.05), MPA-C0 and MPA-C2 were slightly higher than those in the control group (P>0.05), MPA-C2, MPA-C4 and MPA-AUC0-4 were slightly lower than those in the infected group (P>0.05), except for MPA-C0. There was no significant difference in concentration and MPA-AUC0-4 between the control group and the control group (P>0.05). Conclusion MPA-AUC0-4 and MPA-C4 have early predictive significance for the occurrence of infection in renal transplant recipients. The monitoring of mycophenolic acid concentration is helpful for the prevention and control of infection in renal transplant recipients.

Conclusion

MPA-C4 and MPA-AUC0-4 possess an early predictive value for infection of renal transplant recipients.. Monitoring MPA concentration is helpful for prevention and control of infection in renal transplant recipients.

Key words: Mycophenolic acid, Therapeutic monitoring, Infection, Renal transplantation
表1 感染组与对照组肾移植受者基本情况分析
? 感染组(n=48) 对照组(n=68) P值
男:女 36:12 49:19 -
平均年龄(岁) 40.32±9.28 38.81±10.90 0.325
移植后时间(月) 32.50(12.00-68.00) 30.50(10.00-71.00) 0.821
RBC(×1012/mL) 4.14±0.80 4.64±0.75 0.001
HGB(g/L) 116.32±20.89 133.09±20.81 <0.01
HCT(L/L) 0.38±0.06 0.43±0.07 <0.01
CREA(mmol/L) 152.50±68.20 100.64±19.87 <0.01
BUN(mmol/L) 7.32±2.63 6.24±1.74 0.080
eGFR(ml/min) 60.21±21.82 79.21±18.15 0.031
AST(U/L) 20.50(16.32，26.57) 20.86(16.77，23.21) 0.302
ALT(U/L) 23.00(14.00-47.00) 22.00(13.00-45.00) 0.510
GGT(U/L) 27(17.75，63) 24.50(17.54，29.25) 0.312
表2 感染组和稳定组肾移植受者药物浓度和AUC分析
? TAC-C0(ng/ml) MPA-C0(ng/ml) MPA-C0.5(ng/ml) MPA-C2(ng/ml) MPA-C4(ng/ml) MPA-AUC0-4(mg·ml-1·min)
感染组 ? ? ? ? ? ?
? 入院前 5.65±1.94 3.73±1.86 17.65±10.04 7.90±3.66 5.67±2.78* 72.45±19.48*
? 入院时 5.83±2.72 2.39±1.48* 17.20±10.42 6.03±2.24 3.45±1.32 59.51±19.69
? 出院时 5.80±2.30 3.18±1.38 16.80±6.37 7.11±2.34 3.80±2.03 60.62±16.18
对照组 5.39±1.81 3.43±1.68 17.82±6.98 7.29±1.99 3.86±1.57 61.85±12.89
[1]
Staatz CE,Tett SE. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients[J]. Clin pharmacokinet, 2007,46(1):13-58.
[2]
Van Gelder T,Le Meur Y,Shaw LM, et al. Therapeutic drug monitoring of mycophenolate mofetil in transplantation[J]. Ther Drug Monit, 2006,28(2):145-154.
[3]
Kiang TK,Ensom MH. Therapeutic drug monitoring of mycophenolate in adult solid organ transplant patients: an update[J]. Expert Opin Drug Metab Toxicol, 2016,12(5):545-553.
[4]
Andrews LM,Li Y,De Winter BCM, et al. Pharmacokinetic considerations related to therapeutic drug monitoring of tacrolimus in kidney transplant patients[J]. Expert Opin Drug Metab Toxicol, 2017,13(12):1225-1236.
[5]
Staatz CE,Tett SE. Pharmacology and toxicology of mycophenolate in organ transplant recipients: an update[J]. Arch Toxicol, 2014,88(7):1351-1389.
[6]
Ham JY,Jung HY,Choi JY, et al. Usefulness of mycophenolic acid monitoring with PETINIA for prediction of adverse events in kidney transplant recipients[J]. Scand J Clin Lab Invest, 2016,76(4):296-303.
[7]
Daher Abdi Z,Prémaud A,Essig M, et al. Exposure to mycophenolic acid better predicts immunosuppressive efficacy than exposure to calcineurin inhibitors in renal transplant patients[J]. Clin Pharmacol Ther, 2014,96(4):508-515.
[8]
于立新，周敏捷，罗敏. 肾移植受者应用霉酚酸酯的合理治疗窗[J]. 南方医科大学学报, 2014,34(12):1842-1845.
[1] 农云洁, 黄小桂, 黄裕兰, 农恒荣. 超声在多重肺部感染诊断中的临床应用价值[J/OL]. 中华医学超声杂志（电子版）, 2024, 21(09): 872-876.
[2] 姜珊, 李湘燕, 田硕涵, 温冰, 何睿, 齐心. 采用优化抗感染治疗模式改善糖尿病足感染预后的临床观察[J/OL]. 中华损伤与修复杂志(电子版), 2024, 19(05): 398-403.
[3] 梁孟杰, 朱欢欢, 王行舟, 江航, 艾世超, 孙锋, 宋鹏, 王萌, 刘颂, 夏雪峰, 杜峻峰, 傅双, 陆晓峰, 沈晓菲, 管文贤. 联合免疫治疗的胃癌转化治疗患者预后及术后并发症分析[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 619-623.
[4] 许月芳, 刘旺, 曾妙甜, 郭宇姝. 多粘菌素B和多粘菌素E治疗外科多重耐药菌感染临床疗效及安全性分析[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 700-703.
[5] 中华医学会器官移植学分会. 遗体捐献肾脏获取手术技术操作指南[J/OL]. 中华移植杂志(电子版), 2024, 18(05): 257-265.
[6] 皮尔地瓦斯·麦麦提玉素甫, 李慧灵, 艾克拜尔·艾力, 李赞林, 王志, 克力木·阿不都热依木. 生物补片修补巨大复发性腹壁切口疝临床疗效分析[J/OL]. 中华疝和腹壁外科杂志(电子版), 2024, 18(06): 624-628.
[7] 顾熙, 徐子宇, 周澍, 张吴楼, 张业鹏, 林昊, 刘宗航, 嵇振岭, 郑立锋. 腹股沟疝腹膜前间隙无张力修补术后补片感染10 例报道[J/OL]. 中华疝和腹壁外科杂志(电子版), 2024, 18(06): 665-669.
[8] 臧宇, 姚胜, 朱新勇, 戎世捧, 田智超. 低温等离子射频消融治疗腹壁疝术后补片感染的临床效果[J/OL]. 中华疝和腹壁外科杂志(电子版), 2024, 18(06): 687-692.
[9] 杨闯, 马雪. 腹壁疝术后感染的危险因素分析[J/OL]. 中华疝和腹壁外科杂志(电子版), 2024, 18(06): 693-696.
[10] 邢嘉翌, 龚佳晟, 祝佳佳, 陆群. 肺癌化疗患者继发肺部感染的病原菌耐药性及炎症因子变化分析[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(05): 714-718.
[11] 王石林, 叶继章, 丘向艳, 陈桂青, 邹晓敏. 慢性阻塞性肺疾病真菌感染风险早期预测分析[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(05): 773-776.
[12] 中华医学会器官移植学分会. 肝移植术后缺血性胆道病变诊断与治疗中国实践指南[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 739-748.
[13] 丛黎, 马林, 陈旭, 李文文, 张亮亮, 周华亭. 改良CT严重指数联合炎症指标在重症急性胰腺炎患者胰腺感染预测及预后评估中的研究[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(05): 432-436.
[14] 贾玲玲, 滕飞, 常键, 黄福, 刘剑萍. 心肺康复在各种疾病中应用的研究进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(09): 859-862.
[15] 颜世锐, 熊辉. 感染性心内膜炎合并急性肾损伤患者的危险因素探索及死亡风险预测[J/OL]. 中华临床医师杂志(电子版), 2024, 18(07): 618-624.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号